Alpha Emitter Radium-223 and Survival in Metastatic Prostate CancerChris Parker, Oliver Sartor, Nicholas D. James et al.|New England Journal of Medicine|2013Cited by 3.3k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Howard I. Scher, Andrew J. Armstrong, Michael J. Morris et al.|Journal of Clinical Oncology|2016Cited by 1.6k
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trialOliver Sartor, Christopher Parker, Robert L. Coleman et al.|The Lancet Oncology|2014Cited by 491
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)Niven Mehra, Johann S. de Bono, David Dolling et al.|European Urology|2018Cited by 110
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNASemini Sumanasuriya, Johann S. de Bono, George Seed et al.|European Urology|2021Cited by 65